Compare Gilead Sciences, Inc. (GILD) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $151.08 (market cap $182.40B), while Vanguard Real Estate Index Fund ETF trades at $90.36 (market cap $70.80B). The key difference: Gilead Sciences, Inc. is far larger — about 2.6× Vanguard Real Estate Index Fund ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Real Estate Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Real Estate Index Fund ETF for 112 Days on average.
| GILD | VNQ | |
|---|---|---|
Market Cap | $182.40B | $70.80B |
Volume | 4,469,821 | 6,073,580 |
Sector | Health | — |
52-Week High | $155.80 | $100.95 |
52-Week Low | $116.74 | $87.00 |
Typical Hold Time | 111 Days | 112 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
VNQ trades at $90.02, up 1.5% today amid a bearish technical trend. The ETF faces pressure from rising Treasury yields, with moving averages signaling sell conditions. Recent news highlights institutional buying despite sector headwinds, as REITs grapple with interest rate sensitivity and valuation concerns. The dividend yield remains a focal point, though competition from T-bills challenges its income appeal.
Outlook: Near-term risks from Fed policy and sector rotation persist, but contrarian opportunities exist for long-term investors. Key risks include interest rate volatility and economic slowdowns, while potential upside hinges on rate stabilization and real estate demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
